A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd Line Chronic Phase ? Chronic Myelogenous Leukemia (ASC2ESCALATE)
Clinical Trial Grant
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
May 25, 2023
End Date
December 31, 2028
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
May 25, 2023
End Date
December 31, 2028